JUNSHI BIO announced that the company recently received the "Acceptance Notice" issued by the National Medical Products Administration, and the clinical trial application for injectable JS212 (project code "JS212") has been accepted. The acceptance number is CXSL2500023. JS212 is a recombinant humanized dual-specific antibody conjugate drug targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), primarily used for the treatment of advanced malignant solid tumors.
君实生物：注射用JS212临床试验申请获受理
JUNSHI BIO: The clinical trial application for injectable JS212 has been accepted.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated